Discover

Back to filter

Related topics

Curiox webinar - how to retain more cells for Single Cell Sequencing and proteogenomics ?

Curiox

Feb 15, 2021

Curiox Laminar Wash technology has been added as part of the official BioLegend TotalSeq...

Cytek Aurora in Action : how to easily resolve highly overlapping dyes ?

Cytek Biosciences

Feb 2, 2021

Learn from Jeff Nelson, a manager of a cytometry shared resource laboratory, about the...

Webinar: A simple Migration/Invasion workflow using IncuCyte Live-cell analysis system

Sartorius

Jan 27, 2021

Cell migration and invasion, or cell motility, play a role in many normal and...

Webinar : meet the Cytek's new cFluor reagents

Cytek Biosciences

Jan 25, 2021

Cytek Biosciences has already redefined what is possible in flow cytometry. The new Cytek...

Introducing Cytek cFluor, 14 Colors Immunoprofiling Kit

Cytek Biosciences

Jan 19, 2021

Cytek cFluor Immunoprofiling Kit allows for the identification of helper T cells,...

Cytek full Spectrum flow Cytometry webinar: Part II – panel design and troubleshooting

Cytek Biosciences

Jan 11, 2021

In this session, we will continue to look at full spectrum flow cytometry and look at considerations for fluorescence...

IncuCyte for in-vitro analysis of SARS-CoV-2 vaccine candidate

Sartorius

Jan 4, 2021

Watch this video to learn how researcher at Humane Genomics are utilizing the Incucyte...

Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice

Precision X-Ray

Dec 29, 2020

Radio-active sources have been used routinely for the preconditioning in humanized mouse...

Advances in Leukemia research using shear flow and Bioflux system

Fluxion Biosciences

Dec 10, 2020

Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes...

Do you have our CellRad benchtop irradiator? It’s the only one on the market!

Precision X-Ray

Dec 9, 2020

The CellRad is a smaller, simpler, safer, and more cost effective alternative to...

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey